A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Also Known as Sevikar
You'll have option to make 4 interest-free payments by credit card once your order is confirmed using
Azor is a prescription medication for the treatment of hypertension (high blood pressure) in adults. Many people with high blood pressure require more than one drug for treatment, and Azor offers a convenient solution by combining two drugs into one tablet.
High blood pressure is one of the most common chronic diseases. It can go undetected for years and can significantly increases the risk of heart disease and blood vessel problems.
Azor works by lowering blood pressure to a safer level.
The starting dosage is usually Azor 5-20 mg once daily. The dosage may be increased to a maximum of 10-40 mg once daily.
The active ingredients in Azor are amlodipine and olmesartan.
Drugs that can interact with Azor may include:
Your blood pressure and kidney function should be monitored when starting this drug and throughout treatment.
Tell your doctor if you experience any edema (swelling).
Tell your doctor if you experience chest pain when starting or changing dosages.
Common adverse reactions are:
Azor [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2016.